Published in J Exp Med on February 21, 2000
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 1.96
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A (2002) 1.38
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol (2002) 1.09
Elements of cancer immunity and the cancer-immune set point. Nature (2017) 1.05
Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A (2001) 1.04
Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci U S A (2001) 1.03
IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci U S A (2004) 1.00
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A (2010) 0.99
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res (2002) 0.98
Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer (2001) 0.91
Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002) 0.88
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother (2004) 0.87
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun (2008) 0.85
A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res (2010) 0.82
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs (2013) 0.82
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) (2015) 0.80
NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability. Int J Cancer (2012) 0.78
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology (2016) 0.78
Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE). PLoS One (2009) 0.78
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother (2009) 0.77
Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma. Immunology (2009) 0.77
Immunotherapy of melanoma. Immunology (2001) 0.76
Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer (2014) 0.76
How much help does a vaccine-induced T-cell response need? J Clin Invest (2001) 0.75
Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant. PLoS One (2014) 0.75
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 9.31
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med (1996) 5.29
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med (1997) 4.01
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
B cells inhibit induction of T cell-dependent tumor immunity. Nat Med (1998) 2.50
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst (1996) 1.72
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 1.70
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res (1992) 1.65
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med (1999) 1.58
Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol Immunother (1994) 1.19
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Tumor necrosis factor (TNF). Science (1985) 8.80
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J Cell Biol (1998) 5.03
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Improved complementation in the cytotoxic test. Transplantation (1970) 3.93
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Wheat germ agglutinin. Molecular characteristics and specificity for sugar binding. J Biol Chem (1974) 3.80
G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients. Epidemiology (1992) 3.79
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Glycogen storage disease in adults. Ann Intern Med (1994) 3.58
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Ly-C: a third locus specifying alloantigens expressed only on thymocytes and lymphocytes. Transplantation (1971) 3.42
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
New paths in human cancer serology. J Exp Med (1998) 3.12
Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.06
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79